0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2001;161(18):2173. doi:10.1001/archinte.161.18.2173.
Text Size: A A A
Published online

COMPARISON OF THE ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN WITH ENOXAPARIN AND PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT: A PHASE 2 DOSE-FINDING STUDY

In a dose-finding study, the authors tested the administration of 4 fixed doses of oral ximelagtran twice daily starting after elective total knee replacement as prophylaxis against venous thromboembolism and compared the most effective ximelagatran dose with 30 mg of enoxaparin sodium subcutaneously twice daily starting 12 to 24 hours after surgery. The 6- to 12-day rates of overall venous thromboembolism (and proximal deep vein thrombosis or pulmonary embolism) for the 8-, 12-, 18-, and 24-mg doses of ximelagatran twice daily were 27% (6.6%), 19.8% (2.0%), 28.7% (5.8%), and 15.8% (3.2%), respectively. The rates of overall venous thromboembolism (22.7%) and proximal deep vein thrombosis or pulmonary embolism (3.1%) for enoxaparin did not differ significantly compared with the 24-mg dose of ximelagatran twice daily (overall difference, −6.9%; 95% confidence interval, −18.0% to 4.2%; P = .3). There was no major bleeding with 24 mg of ximelagatran twice daily. Fixed dose, unmonitored ximelagatran, 24 mg twice daily, starting after surgery seems to be safe and effective oral prophylaxis against venous thromboembolism after total knee replacement.

See Article

AN EVALUATION OF CHOOSE TO MOVE 1999: AN AMERICAN HEART ASSOCIATION PHYSICAL ACTIVITY PROGRAM FOR WOMEN

Choose to Move is a 12-week self-help lifestyle intervention program designed by the American Heart Association for women across the United States. The purpose of this study was to evaluate the impact of the 1999 Choose to Move Program on women's physical activity, diet, and knowledge about heart disease and stroke. Of the 23 171 participants, 90% were white and 56% were aged 35 to 54 years. Women who completed the biweekly evaluations (n = 6389 at 2 weeks to 3775 at 12 weeks) reported significantly increased levels of physical activity, reduced consumption of high-fat foods, and increased knowledge of symptoms of heart attack or stroke. This program provides an important model for public health, voluntary, and other health organizations of population-based, low-cost self-help programs that support the Healthy People 2010 objectives for physical activity, nutrition, and cardiovascular health.

See Article

GALLSTONE DISEASE AND RELATED RISK FACTORS IN PATIENTS WITH CROHN DISEASE: ANALYSIS OF 330 CONSECUTIVE CASES

The prevalence of gallstone disease was significantly higher in 330 consecutive patients with Crohn disease than it was in the general population (24.0% vs 13.8%). Age, site of disease at diagnosis, and the presence, number, and site of bowel resections were independently associated with gallstone disease at multivariate analysis.

See Article

COSTS OF HEPATITIS C

Hepatitis C has been called the "epidemic of the new millennium." Annual deaths from hepatitis C within the United States may surpass those from acquired immunodeficiency syndrome (AIDS) by 2010. Little is known about the annual costs of hepatitis C. In this study, standard techniques are used that split the costs into categories such as medical spending and lost wages. Total costs were estimated to be $5.5 billion in 1997, which significantly exceeds the only other hepatitis C estimate ($0.6 billion) for the 1990s; however, it is less than the annual costs of AIDS ($30 billion in 1992). Hepatitis C costs will rise considerably in the future as more people manifest symptoms and die.

See Article

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.